• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome. Read More

Bria-IMT Combo Outperforms Other Metastatic Breast Cancer Treatments

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer. Read More

Sometimes, Distractions Help During Breast Cancer

by MM360 Staff | Apr 16, 2025 | Uncategorized

Source: CureToday articles After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life’s beauty. Read More

Understanding the Use of Bispecific Antibodies in Multiple Myeloma

by | Apr 4, 2025 | Uncategorized

Source: CureToday articles Bispecific antibodies target specific cells, offering effective treatment for relapsed/refractory multiple myeloma, with varying side effect profiles. Read More

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

by | Apr 4, 2025 | Uncategorized

Source: CureToday articles CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials. Read More

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

by | Apr 1, 2025 | Uncategorized

Source: CureToday articles Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit. Read More
« Older Entries
Next Entries »

Recent Content

  • Molecular profiling and risk stratification in solitary bone plasmacytoma
  • Safety and Efficacy of Bispecific Antibody Treatment in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis of Proportions from Clinical Trials
  • Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study
  • Plasmapheresis facilitates soluble BCMA clearance and contributes to reversing primary resistance to anti-BCMA immunotherapy in multiple myeloma
  • Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma
  • A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients
  • Subcutaneous Bortezomib Associated With Reduced Incidence of Peripheral Neuropathy in Multiple Myeloma
  • Multiple Myeloma: Key Insights on Diagnosis and Evolving Treatment Strategies
  • Multiple myeloma associated long non-coding RNA PLUM confers chemoresistance by enhancing PRC2 mediated UPR pathway activation
  • Mobilization of hematopoietic stem cells using G-CSF with or without cyclophosphamide before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma receiving induction therapy with or without daratumumab
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT